The federal government is launching a coordinated effort to establish standardized ways of evaluating artificial intelligence tools used in clinical care. The White House's Office of Science and Technology Policy, the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology are convening experts for a one-month "sprint" to develop what they're calling "a consensus set of principles" for benchmarking and evaluating clinical artificial intelligence.

Why Is the Government Getting Involved in AI Standards Now?

As AI tools increasingly make their way into hospitals, clinics, and diagnostic workflows, there's a growing recognition that the healthcare system lacks a unified framework for assessing whether these tools actually work as promised. Right now, different AI applications might be evaluated using different metrics, making it difficult for doctors, hospital administrators, and regulators to compare performance or understand which tools are genuinely reliable. The government's initiative aims to solve that problem by bringing together experts to hammer out shared principles that could guide how clinical AI gets tested and validated going forward.

This effort reflects a broader shift in how policymakers are thinking about health technology. Rather than waiting for problems to emerge after AI tools are already in use, federal agencies are trying to get ahead of the curve by establishing evaluation standards before widespread adoption becomes the norm.

How Will This Sprint Process Work?

According to the invitation reviewed by health technology reporters, the initiative is structured in two phases. The first involves a written phase where experts submit their input on benchmarking and evaluation approaches. This is followed by a discussion phase where participants can debate, refine, and build consensus around the principles that emerge. The entire process is designed to move quickly, compressed into a single month, which suggests the government sees this as an urgent priority.

The involvement of three separate federal entities,the White House's science office, the FDA, and the Office of the National Coordinator for Health Information Technology,signals that this is a coordinated, high-level initiative. The FDA's participation is particularly significant, since the agency already regulates medical devices and software, and will likely play a role in implementing whatever standards emerge from this process.

Steps to Understanding Clinical AI Evaluation

• Benchmarking: Establishing standardized tests that measure how well an AI tool performs on specific clinical tasks, similar to how medications are tested in clinical trials before approval.
• Real-World Validation: Ensuring that AI tools work as expected not just in controlled research settings, but in actual hospital and clinic environments where patient care happens.
• Transparency and Explainability: Requiring that AI systems can explain their reasoning to clinicians, so doctors understand why the tool made a particular recommendation or diagnosis.
• Equity Assessment: Testing whether AI tools perform equally well across different patient populations, ages, races, and genders, to avoid perpetuating healthcare disparities.
• Ongoing Monitoring: Establishing systems to track how AI tools perform over time and in different clinical contexts, rather than assuming performance remains constant.

What makes this government initiative noteworthy is that it's happening at a moment when clinical AI adoption is accelerating. Health systems are already deploying AI tools for everything from diagnostic imaging analysis to predicting patient deterioration to administrative tasks like scheduling. Without clear evaluation standards, there's a risk that some tools could be adopted based on marketing claims rather than rigorous evidence of clinical benefit.

The consensus-building approach also reflects recognition that no single federal agency can solve this problem alone. The FDA regulates some AI tools as medical devices, but not all. Medicare and insurance companies make coverage decisions based on their own assessments. Hospital systems make purchasing decisions based on vendor claims and peer recommendations. By bringing all these stakeholders together to agree on shared principles, the government is trying to create a common language and framework that could influence how AI tools get developed, tested, and deployed across the entire healthcare system.

The results of this one-month sprint could shape how clinical AI evolves for years to come. If the government succeeds in establishing principles that gain broad acceptance, they could become the de facto standard for evaluating new AI tools in healthcare. If the process stalls or produces principles that stakeholders don't embrace, the healthcare system may continue down its current path of fragmented, inconsistent evaluation approaches.